Stock listing
Lang & Schwarz:A41ES4 Veru Inc. Aktie
German listing (Lang & Schwarz) of Veru Inc. · home listing NASDAQ:VERU
Follow Veru Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:VERU
$1.94 USD -0.37 (-16.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:VERU
- Day range
- $1.93 – $2.17 USDNov 20, 2026
- Volume
- 247,921 sharesNov 20, 2026
- Market cap
- $33.08M USDAt the close on Nov 20, 2026 · price × 17.05M shares outstanding
- 52-week range
- $1.93 – $7.33 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $468,881 USDMedian day 130,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:VERU · Home | $1.94 USD | -0.37 (-16.0%) | 247,921 | $2.09 | $2.17 | $1.93 | $2.31 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:VERU · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.94 | -0.37 | -16.0% | $2.09 | $2.17 | $1.93 | 247,921 | |
| $2.31 | +0.17 | +7.9% | $2.16 | $2.34 | $2.13 | 467,111 | |
| $2.14 | +0.06 | +2.9% | $2.09 | $2.20 | $2.075 | 305,002 | |
| $2.08 | -0.01 | -0.5% | $2.08 | $2.14 | $2.03 | 198,888 | |
| $2.09 | -0.03 | -1.4% | $2.15 | $2.15 | $2.08 | 90,524 | |
| $2.12 | -0.02 | -0.9% | $2.10 | $2.15 | $2.079 | 91,575 | |
| $2.14 | +0.02 | +0.9% | $2.13 | $2.17 | $2.071 | 38,942 | |
| $2.12 | -0.07 | -3.2% | $2.17 | $2.21 | $2.06 | 128,464 | |
| $2.19 | +0.07 | +3.3% | $2.12 | $2.21 | $2.105 | 134,522 | |
| $2.12 | +0.06 | +2.9% | $2.08 | $2.15 | $2.07 | 137,144 | |
| $2.06 | -0.14 | -6.4% | $2.20 | $2.20 | $2.04 | 214,771 | |
| $2.20 | +0.04 | +1.9% | $2.18 | $2.23 | $2.10 | 180,514 | |
| $2.16 | 0.00 | 0.0% | $2.18 | $2.22 | $2.11 | 103,489 | |
| $2.16 | -0.03 | -1.4% | $2.20 | $2.22 | $2.075 | 249,370 | |
| $2.19 | -0.04 | -1.8% | $2.25 | $2.26 | $2.16 | 78,878 | |
| $2.23 | -0.04 | -1.8% | $2.27 | $2.33 | $2.22 | 56,935 | |
| $2.27 | -0.01 | -0.4% | $2.27 | $2.30 | $2.24 | 73,162 | |
| $2.28 | +0.07 | +3.2% | $2.22 | $2.34 | $2.22 | 157,711 | |
| $2.21 | -0.03 | -1.3% | $2.25 | $2.26 | $2.18 | 86,578 | |
| $2.24 | -0.05 | -2.2% | $2.29 | $2.32 | $2.22 | 122,600 | |
| $2.29 | -0.01 | -0.4% | $2.30 | $2.30 | $2.24 | 85,800 | |
| $2.30 | -0.08 | -3.4% | $2.37 | $2.41 | $2.28 | 99,800 | |
| $2.38 | +0.07 | +3.0% | $2.31 | $2.40 | $2.31 | 89,700 | |
| $2.31 | +0.01 | +0.4% | $2.30 | $2.35 | $2.27 | 88,100 | |
| $2.30 | -0.14 | -5.7% | $2.41 | $2.48 | $2.27 | 305,400 | |
| $2.44 | +0.31 | +14.6% | $2.14 | $2.48 | $2.12 | 505,300 | |
| $2.13 | -0.06 | -2.7% | $2.26 | $2.29 | $2.11 | 275,200 | |
| $2.19 | -0.22 | -9.1% | $2.41 | $2.42 | $2.18 | 169,200 | |
| $2.41 | -0.05 | -2.0% | $2.44 | $2.45 | $2.40 | 85,500 | |
| $2.46 | +0.04 | +1.7% | $2.42 | $2.49 | $2.42 | 128,900 | |
| $2.42 | -0.04 | -1.6% | $2.44 | $2.52 | $2.39 | 147,600 | |
| $2.46 | -0.01 | -0.4% | $2.42 | $2.54 | $2.41 | 202,400 | |
| $2.47 | -0.08 | -3.1% | $2.54 | $2.75 | $2.44 | 1,517,500 | |
| $2.55 | +0.04 | +1.6% | $2.51 | $2.62 | $2.50 | 88,600 | |
| $2.51 | -0.03 | -1.2% | $2.56 | $2.56 | $2.50 | 104,900 | |
| $2.54 | -0.12 | -4.5% | $2.65 | $2.65 | $2.53 | 70,700 | |
| $2.66 | +0.10 | +3.9% | $2.58 | $2.70 | $2.51 | 183,000 | |
| $2.56 | +0.03 | +1.2% | $2.53 | $2.58 | $2.50 | 33,100 | |
| $2.53 | -0.01 | -0.4% | $2.52 | $2.57 | $2.51 | 101,300 | |
| $2.54 | +0.03 | +1.2% | $2.55 | $2.57 | $2.50 | 115,800 | |
| $2.51 | +0.05 | +2.0% | $2.42 | $2.52 | $2.42 | 87,400 | |
| $2.46 | -0.04 | -1.6% | $2.49 | $2.51 | $2.43 | 94,000 | |
| $2.50 | +0.06 | +2.5% | $2.46 | $2.52 | $2.42 | 121,400 | |
| $2.44 | +0.03 | +1.2% | $2.44 | $2.49 | $2.43 | 158,200 | |
| $2.41 | +0.02 | +0.8% | $2.39 | $2.44 | $2.36 | 102,900 | |
| $2.39 | +0.07 | +3.0% | $2.35 | $2.40 | $2.35 | 93,900 | |
| $2.32 | -0.02 | -0.9% | $2.34 | $2.37 | $2.31 | 130,300 | |
| $2.34 | 0.00 | 0.0% | $2.36 | $2.36 | $2.29 | 125,300 | |
| $2.34 | -0.10 | -4.1% | $2.41 | $2.44 | $2.34 | 207,500 | |
| $2.44 | -0.06 | -2.4% | $2.52 | $2.53 | $2.43 | 239,300 | |
| $2.50 | +0.02 | +0.8% | $2.52 | $2.53 | $2.46 | 181,400 | |
| $2.48 | -0.10 | -3.9% | $2.59 | $2.59 | $2.48 | 264,800 | |
| $2.58 | -0.06 | -2.3% | $2.81 | $2.85 | $2.55 | 1,340,500 | |
| $2.64 | -0.01 | -0.4% | $2.65 | $2.73 | $2.63 | 143,500 | |
| $2.65 | -0.10 | -3.6% | $2.75 | $2.77 | $2.65 | 75,400 | |
| $2.75 | +0.06 | +2.2% | $2.70 | $2.76 | $2.65 | 202,600 | |
| $2.69 | -0.11 | -3.9% | $2.80 | $2.82 | $2.69 | 203,200 | |
| $2.80 | +0.17 | +6.5% | $2.63 | $2.83 | $2.59 | 250,000 | |
| $2.63 | -0.11 | -4.0% | $2.71 | $2.73 | $2.61 | 92,700 | |
| $2.74 | -0.06 | -2.1% | $2.82 | $2.84 | $2.71 | 122,500 | |
| $2.80 | +0.09 | +3.3% | $2.73 | $2.82 | $2.70 | 169,400 | |
| $2.71 | +0.12 | +4.6% | $2.60 | $2.79 | $2.60 | 227,020 | |
| $2.59 | -0.05 | -1.9% | $2.64 | $2.64 | $2.50 | 102,569 | |
| $2.64 | +0.06 | +2.3% | $2.56 | $2.68 | $2.56 | 177,500 | |
| $2.58 | -0.06 | -2.3% | $2.65 | $2.68 | $2.52 | 135,400 |
Splits
1 split · NASDAQ:VERU · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation |
- Ticker
- Lang & Schwarz:A41ES4
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Nov 17, 2026
Veru Presents New Results at ObesityWeek 2026: GLP-1 Weight Loss in Older Adults Associated with Physical Function Decline; Adding Enobosarm Preserved Significant Lean Mass and Physical Function
Latest earnings call · Aug 10, 2026
Veru (NASDAQ:VERU) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 16, 2026
Obesity Week 2026
Conference · 15 slides
Calls
Replays
Veru (NASDAQ:VERU) Q3 2026 Earnings Call
Mon, Aug 10, 2026 · 8:00 AM ET
Watch TranscriptVeru (NASDAQ:VERU) Q2 2026 Earnings Call
Wed, May 13, 2026 · 8:00 AM ET
Watch TranscriptVeru (NASDAQ:VERU) Q1 2026 Earnings Call
Wed, Feb 04, 2026 · 8:00 AM ET
Watch Transcript
Latest news
Veru Presents New Results at ObesityWeek 2026: GLP-1 Weight Loss in Older Adults Associated with Physical Function Decline; Adding Enobosarm Preserved Significant Lean Mass and Physical Function
Nov 17, 2026
Closed $2.14 (+2.9%) on Nov 17, 2026
Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026
Nov 9, 2026
Closed $2.19 (+3.3%) on Nov 9, 2026
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
Sep 8, 2026
Closed $2.58 (-2.3%) on Sep 8, 2026
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
Sep 2, 2026
Closed $2.75 (+2.2%) on Sep 2, 2026
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
Aug 10, 2026
Closed $2.77 (+18.9%) on Aug 10, 2026
Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
Aug 4, 2026
Closed $2.37 (+4.9%) on Aug 4, 2026
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
Aug 3, 2026
Closed $2.26 (+0.9%) on Aug 3, 2026
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
Jul 30, 2026
Closed $2.22 (+0.5%) on Jul 30, 2026
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
Jul 27, 2026
Closed $2.28 (+1.3%) on Jul 27, 2026
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
Jul 7, 2026
Closed $2.88 (+1.8%) on Jul 7, 2026
Financings
Public offering of common stock (or pre-funded warrants) with accompanying Series A and Series B warrants
Dec 17, 2025
Closed: US$23.4M raised · US$3 a share · Canaccord Genuity LLC +1
Dealers: Canaccord Genuity LLC (co-lead), Oppenheimer & Co. Inc. (co-lead)
Use of proceeds: To start the Phase 2b PLATEAU clinical trial of enobosarm
Announced Oct 29, 2025 · Update Oct 30, 2025 · Closed Dec 17, 2025
Decks
Obesity Week 2026
Conference · 15 slides · Nov 16, 2026
2026 Cantor Global Healthcare Conference
Conference · 59 slides · September 2026
Q2 2026 Earnings Presentation
Earnings · 8 slides · May 13, 2026
4th Edition of World Obesity and Weight Management Congress 2024
Conference · 34 slides · Oct 24, 2024
Veru Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 150 in all · newest Nov 17, 2026 · oldest 2019
- Calls
- 19 calls with a replay · 19 with a transcript · latest Aug 10, 2026
- Decks
- 40 decks · latest Nov 16, 2026
Where Veru Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:VERU · Home listing | NASDAQ | United States | USD |
| BOATS:VERU | BOATS | United States | USD |
| gettex:FMW0 | gettex | Germany | EUR |
| Frankfurt:FMW0 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A41ES4 · This page | Lang & Schwarz | Germany | EUR |
| LS Exchange:A41ES4 | LS Exchange | Germany | EUR |
| Munich:FMW0 | Munich | Germany | EUR |
Log in to ask 6ix AI your own questions about Veru Inc.